Company Filing History:
Years Active: 2000-2013
Title: Ann Kwong: Innovator in Hepatitis C Research
Introduction
Ann Kwong is a prominent inventor based in Cambridge, MA, known for her significant contributions to the field of virology, particularly in the study and treatment of Hepatitis C virus (HCV). With a total of seven patents to her name, she has made remarkable strides in developing therapeutic strategies against HCV.
Latest Patents
Among her latest patents, one focuses on Hepatitis C virus variants. This invention relates to HCV variants that are resistant to protease inhibitors such as VX-950. It also provides methods and compositions related to these variants, including techniques for isolating, identifying, and characterizing multiple viral variants from a patient. Another notable patent involves combination therapy for the treatment of HCV infection. This invention details therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor, specifically including VX-950. The patent outlines methods for using these combinations to treat HCV infection and alleviate symptoms in patients, along with providing kits that include these therapeutic combinations.
Career Highlights
Ann Kwong is currently associated with Vertex Pharmaceuticals, Inc., where she continues her groundbreaking work in HCV research. Her innovative approaches have positioned her as a key figure in the development of effective treatments for this challenging virus.
Collaborations
She collaborates with esteemed colleagues, including Chao Lin and Ursula A Germann, to further advance research in this critical area of medicine.
Conclusion
Ann Kwong's contributions to Hepatitis C research through her patents and collaborations highlight her as a leading inventor in the field. Her work not only enhances our understanding of HCV but also paves the way for more effective treatments for patients worldwide.